In the September edition of the Hardman Monthly Newsletter, Dr Martin Hall - based partly on his personal experiences as a long-standing investment analyst - addresses various accounting issues that are highly relevant to today's investors. In particular, he concludes that measuring company cash flow - and especially projecting future cash flows - is pivotal to undertaking rigorous financial analysis, irrespective of how individual companies may present it.
04 Sep 2017
The Monthly September 2017
Abzena (ABZA:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Allergy Therapeutics plc (AGY:LON), 2.7 | Alliance Pharma plc (APH:LON), 36.7 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | Avacta Group PLC (AVCT:LON), 51.0 | Burford Capital Limited (BUR:LON), 1,125 | Chamberlin plc (CMH:LON), 1.7 | Evgen Pharma Plc (EVG:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Woodbois Limited (WBI:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.1 | PPHE Hotel Group Limited (PPH:LON), 1,405 | Primary Health Properties PLC (PHP:LON), 90.8 | R.E.A. Holdings plc (RE:LON), 70.2 | Scancell Holdings Plc (SCLP:LON), 10.2 | Surface Transforms PLC (SCE:LON), 9.6 | Tissue Regenix Group plc (TRX:LON), 69.0 | Oxford BioMedica plc (OXB:LON), 190 | ValiRx PLC (VAL:LON), 3.8
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
The Monthly September 2017
Abzena (ABZA:LON), 0 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | Allergy Therapeutics plc (AGY:LON), 2.7 | Alliance Pharma plc (APH:LON), 36.7 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | Avacta Group PLC (AVCT:LON), 51.0 | Burford Capital Limited (BUR:LON), 1,125 | Chamberlin plc (CMH:LON), 1.7 | Evgen Pharma Plc (EVG:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Woodbois Limited (WBI:LON), 0 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.1 | PPHE Hotel Group Limited (PPH:LON), 1,405 | Primary Health Properties PLC (PHP:LON), 90.8 | R.E.A. Holdings plc (RE:LON), 70.2 | Scancell Holdings Plc (SCLP:LON), 10.2 | Surface Transforms PLC (SCE:LON), 9.6 | Tissue Regenix Group plc (TRX:LON), 69.0 | Oxford BioMedica plc (OXB:LON), 190 | ValiRx PLC (VAL:LON), 3.8
- Published:
04 Sep 2017 -
Author:
Martin Hall -
Pages:
44
In the September edition of the Hardman Monthly Newsletter, Dr Martin Hall - based partly on his personal experiences as a long-standing investment analyst - addresses various accounting issues that are highly relevant to today's investors. In particular, he concludes that measuring company cash flow - and especially projecting future cash flows - is pivotal to undertaking rigorous financial analysis, irrespective of how individual companies may present it.